Different PI 3-kinase inhibitors have distinct effects on endothelial permeability and leukocyte transmigration

International Journal of Biochemistry and Cell Biology

Volumn 44, Issue 11, 2012, Pages 1929-1936

  Cain, Robert J ^a,c   Vanhaesebroeck, Bart ^b   Ridley, Anne J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Endothelium; Permeability; PI3K; PI3K inhibitors; Transendothelial migration

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 5 [(2,2 DIFLUORO 1,3 BENZODIOXOL 5 YL)METHYLIDENE] 2,4 THIAZOLIDINEDIONE; 9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; FOCAL ADHESION KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN P85; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; WORTMANNIN;

ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STIMULATION; DRUG ACTIVITY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKOCYTE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION;

ADENINE; ANDROSTADIENES; ANTIGENS, CD; CADHERINS; CAPILLARY PERMEABILITY; CELL MEMBRANE PERMEABILITY; CELL SHAPE; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; DIOXOLES; ENDOTHELIAL CELLS; FOCAL ADHESION KINASE 2; FURANS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LEUKOCYTES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; PYRIMIDINES; QUINAZOLINES; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TOR SERINE-THREONINE KINASES; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864535429     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2012.07.009     Document Type: Article

References (49)

1. K. Ali, A. Bilancio, M. Thomas, W. Pearce, A.M. Gilfillan, and C. Tkaczyk Essential role for the p110δ phosphoinositide 3-kinase in the allergic response Nature 431 2004 1007 1011
2. S.M. Ali, and D.M. Sabatini Structure of S6 kinase 1 determines whether raptor-mTOR or rictor-mTOR phosphorylates its hydrophobic motif site Journal of Biological Chemistry 280 2005 19445 19448
3. M.J. Allingham, J.D. van Buul, and K. Burridge ICAM-1-mediated, Src- and Pyk2-dependent vascular endothelial cadherin tyrosine phosphorylation is required for leukocyte transendothelial migration Journal of Immunology 179 2007 4053 4064
4. J. Bain, L. Plater, M. Elliott, N. Shpiro, C.J. Hastie, and H. McLauchlan The selectivity of protein kinase inhibitors: a further update Biochemical Journal 408 2007 297 315
5. L.M. Ballou, and R.Z. Lin Rapamycin and mTOR kinase inhibitors Journal of Chemical Biology 1 2008 27 36
6. C.M. Beckers, V.W. van Hinsbergh, and G.P. van Nieuw Amerongen Driving Rho GTPase activity in endothelial cells regulates barrier integrity Thrombosis and Haemostasis 103 2010 40 55
7. R.J. Cain, and A.J. Ridley Phosphoinositide 3-kinases in cell migration Biologie Cellulaire 101 2009 13 29
8. R.J. Cain, B. Vanhaesebroeck, and A.J. Ridley The PI3K p110α isoform regulates endothelial adherens junctions via Pyk2 and Rac1 Journal of Cell Biology 188 2010 863 876
9. M. Camps, T. Ruckle, H. Ji, V. Ardissone, F. Rintelen, and J. Shaw Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis Nature Medicine 11 2005 936 943
10. E. Cernuda-Morollon, and A.J. Ridley Rho GTPases and leukocyte adhesion receptor expression and function in endothelial cells Circulation Research 98 2006 757 767
11. E. Dejana, F. Orsenigo, and M.G. Lampugnani The role of adherens junctions and VE-cadherin in the control of vascular permeability Journal of Cell Science 121 2008 2115 2122
12. A. Denley, S. Kang, U. Karst, and P.K. Vogt Oncogenic signaling of class I PI3K isoforms Oncogene 27 2008 2561 2574
13. J. Doukas, W. Wrasidlo, G. Noronha, E. Dneprovskaia, J. Hood, and R. Soll Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction Biochemical Society Transactions 35 2007 204 206
14. M. Fernandez-Borja, J.D. van Buul, and P.L. Hordijk The regulation of leucocyte transendothelial migration by endothelial signalling events Cardiovascular Research 86 2010 202 210
15. A. Fougerat, S. Gayral, N. Malet, F. Briand-Mesange, M. Breton-Douillon, and M. Laffargue Phosphoinositide 3-kinases and their role in inflammation: potential clinical targets in atherosclerosis? Clinical Science (London) 116 2009 791 804
16. L.C. Foukas, M. Claret, W. Pearce, K. Okkenhaug, S. Meek, and E. Peskett Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation Nature 441 2006 366 370
17. M. Graupera, J. Guillermet-Guibert, L.C. Foukas, L.K. Phng, R.J. Cain, and A. Salpekar Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration Nature 453 2008 662 666
18. R. Heller, Q. Chang, G. Ehrlich, S.N. Hsieh, S.M. Schoenwaelder, and P.J. Kuhlencordt Overlapping and distinct roles for PI3Kβ and γ isoforms in S1P-induced migration of human and mouse endothelial cells Cardiovascular Research 80 2008 96 105
19. E. Hirsch, E. Ciraolo, A. Ghigo, and C. Costa Taming the PI3K team to hold inflammation and cancer at bay Pharmacology & Therapeutics 118 2008 192 205
20. H. Hudry-Clergeon, D. Stengel, E. Ninio, and I. Vilgrain Platelet-activating factor increases VE-cadherin tyrosine phosphorylation in mouse endothelial cells and its association with the PtdIns3′-kinase FASEB Journal 19 2005 512 520
21. N.T. Ihle, and G. Powis The biological effects of isoform-specific PI3-kinase inhibition Current Opinion in Drug Discovery and Development 13 2010 41 49
22. S.P. Jackson, S.M. Schoenwaelder, I. Goncalves, W.S. Nesbitt, C.L. Yap, and C.E. Wright PI 3-kinase p110β: a new target for antithrombotic therapy Nature Medicine 11 2005 507 514
23. Z.A. Knight, B. Gonzalez, M.E. Feldman, E.R. Zunder, D.D. Goldenberg, and O. Williams A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling Cell 125 2006 733 747
24. N. Lambeng, Y. Wallez, C. Rampon, F. Cand, G. Christe, and D. Gulino-Debrac Vascular endothelial-cadherin tyrosine phosphorylation in angiogenic and quiescent adult tissues Circulation Research 96 2005 384 391
25. M. Laplante, and D.M. Sabatini mTOR signaling at a glance Journal of Cell Science 122 2009 3589 3594
26. K.S. Lee, S.J. Park, S.R. Kim, K.H. Min, S.M. Jin, and K.D. Puri Phosphoinositide 3-kinase-δ inhibitor reduces vascular permeability in a murine model of asthma Journal of Allergy and Clinical Immunology 118 2006 403 409
27. Y. Liu, K.R. Shreder, W. Gai, S. Corral, D.K. Ferris, and J.S. Rosenblum Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase Chemistry and Biology 12 2005 99 107
28. R. Marone, V. Cmiljanovic, B. Giese, and M.P. Wymann Targeting phosphoinositide 3-kinase: moving towards therapy Biochimica et Biophysica Acta 1784 2008 159 185
29. J.A. McKenzie, and A.J. Ridley Roles of Rho/ROCK and MLCK in TNF-alpha-induced changes in endothelial morphology and permeability Journal of Cellular Physiology 213 2007 221 228
30. J. Millan, and A.J. Ridley Rho GTPases and leucocyte-induced endothelial remodelling Biochemical Journal 385 2005 329 337
31. S.K. Mitra, D.A. Hanson, and D.D. Schlaepfer Focal adhesion kinase: in command and control of cell motility Nature Reviews Molecular Cell Biology 6 2005 56 68
32. S.J. Parsons, and J.T. Parsons Src family kinases, key regulators of signal transduction Oncogene 23 2004 7906 7909
33. M.D. Potter, S. Barbero, and D.A. Cheresh Tyrosine phosphorylation of VE-cadherin prevents binding of p120- and beta-catenin and maintains the cellular mesenchymal state Journal of Biological Chemistry 280 2005 31906 31912
34. D. Serban, J. Leng, and D. Cheresh H-ras regulates angiogenesis and vascular permeability by activation of distinct downstream effectors Circulation Research 102 2008 1350 1358
35. A.H. Stolpen, E.C. Guinan, W. Fiers, and J.S. Pober Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers American Journal of Pathology 123 1986 16 24
36. S.A. Sturgeon, C. Jones, J.A. Angus, and C.E. Wright Advantages of a selective β-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat European Journal of Pharmacology 587 2008 209 215
37. S. Suire, J. Coadwell, G.J. Ferguson, K. Davidson, P. Hawkins, and L. Stephens p84, a new Gβγ-activated regulatory subunit of the type IB phosphoinositide 3-kinase p110γ Current Biology 15 2005 566 570
38. P. Turowski, R. Martinelli, R. Crawford, D. Wateridge, A.P. Papageorgiou, and M.G. Lampugnani Phosphorylation of vascular endothelial cadherin controls lymphocyte emigration Journal of Cell Science 121 2008 29 37
39. J.D. van Buul, E.C. Anthony, M. Fernandez-Borja, K. Burridge, and P.L. Hordijk Proline-rich tyrosine kinase 2 (Pyk2) mediates vascular endothelial-cadherin-based cell-cell adhesion by regulating beta-catenin tyrosine phosphorylation Journal of Biological Chemistry 280 2005 21129 21136
40. B. Vanhaesebroeck, and D.R. Alessi The PI3K-PDK1 connection: more than just a road to PKB Biochemical Journal 346 Pt 3 2000 561 576
41. B. Vanhaesebroeck, S.J. Leevers, K. Ahmadi, J. Timms, R. Katso, and P.C. Driscoll Synthesis and function of 3-phosphorylated inositol lipids Annual Review of Biochemistry 70 2001 535 602
42. B. Vanhaesebroeck, P.K. Vogt, and C. Rommel PI3K: from the bench to clinic and back Current Topics in Microbiology and Immunology 347 2010 1 19
43. Y. Wallez, F. Cand, F. Cruzalegui, C. Wernstedt, S. Souchelnytskyi, and I. Vilgrain Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site Oncogene 26 2007 1067 1077
44. M.A. Whitehead, M. Bombardieri, C. Pitzalis, and B. Vanhaesebroeck Isoform-selective induction of human p110δ PI3K expression by TNFα: identification of a new and inducible PIK3CD promoter Biochemical Journal 443 2012 857 867
45. B. Wojciak-Stothard, and A.J. Ridley Rho GTPases and the regulation of endothelial permeability Vascular Pharmacology 39 2002 187 199
46. P. Workman, P.A. Clarke, F.I. Raynaud, and R.L. van Montfort Drugging the PI3 kinome: from chemical tools to drugs in the clinic Cancer Research 70 2010 2147 2157
47. Q. Xue, B. Hopkins, C. Perruzzi, D. Udayakumar, D. Sherris, and L.E. Benjamin Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability Cancer Research 68 2008 9551 9557
48. Q. Xue, J.A. Nagy, E.J. Manseau, T.L. Phung, H.F. Dvorak, and L.E. Benjamin Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase Arteriosclerosis, Thrombosis, and Vascular Biology 29 2009 1172 1178
49. Q. Yang, and K.L. Guan Expanding mTOR signaling Cell Research 17 2007 666 681